Subcutaneous daratumumab plus pomalidomide-dexamethasone: an effective treatment option for MM Subcutaneous daratumumab plus pomalidomide-dexamethasone: an effective treatment option for MM ASH 2020 Read more
ASH 2020 Dose-escalation of oral azacitidine provides clinical benefit to acute myeloid leukaemia patie... Read more
EHA 2020 PODCAST: prof. Tiziano Barbui about ropeginterferon in patients with polycythemia vera Read more